Tesamorelin in Australia

Stabilised growth-hormone-releasing hormone analogue. Tesamorelin is a 44-amino-acid GHRH analogue with a trans-3-hexenoic acid modification at the N-terminus that protects it from enzymatic breakdown. It is best known from the HIV-associated lipodystrophy trials, where it reduced visceral abdominal fat without the broad metabolic effects seen with recombinant growth hormone.

Visceral adiposity: cT-measured VAT in the Phase 3 program. GH and IGF-1 axis: pulsatile GH release with intact feedback. Hepatic fat: liver-fat fraction in HIV-associated NAFLD. Body composition: trunk fat versus limb lean mass by DEXA. Cognitive research: executive function endpoints in older adults. Two Phase 3 trials (Falutz et al., NEJM 2007 and JCEM 2010) reported a mean 15–18% reduction in visceral adipose tissue over 26 weeks in HIV-associated lipodystrophy, with reduced triglycerides and no significant change in subcutaneous fat. Later studies examined liver fat in NAFLD and cognitive endpoints in older adults.

The Phase 3 trials reported a mean 15–18% reduction in visceral adipose tissue on CT at 26 weeks, with triglyceride reductions and no significant change in subcutaneous fat; visceral fat returned toward baseline after discontinuation.

Injection-site reactions (erythema, pruritus), joint pain, peripheral oedema and paraesthesia were the most reported events in the Phase 3 program. Because tesamorelin raises IGF-1, the registered product's labelling notes monitoring in the trials.

Published Tesamorelin studies specify their own amounts and routes, and those vary by model and endpoint. Peptide Aus products are supplied for in-vitro laboratory research, so we do not provide dosing, cycle or usage guidance for people. For laboratory preparation, the reconstitution calculator converts vial size and water volume into concentration and syringe units.

Ipamorelin acts on the ghrelin receptor; tesamorelin on the GHRH receptor. Both raise GH, but tesamorelin's evidence base is the visceral-fat trials.

CJC-1295 is also a GHRH analogue; the DAC form is long-acting, tesamorelin is stabilised but short-acting with a clinical trial record.

Sermorelin is unmodified GHRH (1–29) with a half-life of minutes; tesamorelin's N-terminal modification protects it from breakdown.

No. Tesamorelin is registered in the United States (as Egrifta) for a narrow HIV-related indication, but it has not been registered by the TGA, so it is not available through Australian pharmacies or prescribers. Peptide Aus supplies research-grade tesamorelin for laboratory use only.

GLP-1 compounds reduce food intake and produce broad weight loss. Tesamorelin does not change appetite; its published effect is a targeted reduction in visceral fat through the GH axis, with little change in subcutaneous fat or total weight.

5mg is the smallest format for first-run assays, 10mg suits shorter protocols, and 20mg gives the lowest cost per milligram for extended work. All three come from CoA-verified batches.

With bacteriostatic water added slowly down the inside wall of the vial, then swirled gently. Each vial size lists its suggested volume, and the calculator converts volume to concentration.

Lyophilised: −20 °C, sealed, away from light and moisture. Reconstituted: 2–8 °C, used within 8–12 weeks, never frozen.

Tesamorelin is not registered in Australia and has no approved human use here. It is supplied by Peptide Aus for in-vitro laboratory research only. The buyer is responsible for lawful use.

Directly from Peptide Aus, from Australian stock, in 3 vial sizes from $89.99 (5mg) to $259.99 (20mg). Prices are AUD and GST inclusive. Paid orders before 2pm AEST/AEDT dispatch the same business day, tracked.